文献速递浆细胞疾病

新诊断多发性骨髓瘤的巩固与维持治疗

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
PubMed 文献 · J Clin Oncol · 2021-09-14

PURPOSE: To address the role of consolidation treatment for newly diagnosed, transplant eligible patients with multiple myeloma in a controlled clinical trial.…

要点

  • VRD巩固较无巩固显著延长中位PFS(59.3 vs 42.9个月)。
  • 巩固后≥CR率34% vs 18%,含维持后≥CR率59% vs 46%。
  • VRD毒性可接受且可控。

核心结论

  • VRD巩固后持续来那度胺维持较单用维持可改善新诊断适合移植多发性骨髓瘤患者的PFS和缓解深度。

主要发现

  • 226例维持前达CR、sCR或VGPR亚组中,VRD治疗患者MRD阴性率为74%。
  • 修订ISS 3期(HR=2.00;95%CI 1.41-2.86)和amp1q(HR=1.67;95%CI 1.37-2.04)为显著不良预后因素。

关键数值与推荐

  • VRD巩固方案为2周期硼替佐米、来那度胺和地塞米松。
  • 维持治疗为持续来那度胺,中位持续时间33个月(四分位距13-86个月)。

临床怎么用

  • 对新诊断适合移植的多发性骨髓瘤患者,在诱导和强化治疗后可采用2周期VRD巩固,随后持续来那度胺维持以延长PFS。

局限性

  • MRD分析仅限226例维持前达CR、sCR或VGPR的亚组患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To address the role of consolidation treatment for newly diagnosed, transplant eligible patients with multiple myeloma in a controlled clinical trial. PATIENTS AND METHODS: The EMN02/HOVON95 trial compared consolidation treatment with two cycles of bortezomib, lenalidomide, and dexamethasone (VRD) or no consolidation after induction and intensification therapy, followed by continuous lenalidomide maintenance. Primary study end point was progression-free survival (PFS). RESULTS: Eight hundred seventy-eight eligible patients were randomly assigned to receive VRD consolidation (451 patients) or no consolidation (427 patients). At a median follow-up of 74.8 months, median PFS with adjustment for pretreatment was prolonged in patients randomly assigned to VRD consolidation (59.3 v 42.9 months, hazard ratio [HR] = 0.81; 95% CI, 0.68 to 0.96; P = .016). The PFS benefit was observed across most predefined subgroups, including revised International Staging System (ISS) stage, cytogenetics, and prior treatment. Revised ISS3 stage (HR, 2.00; 95% CI, 1.41 to 2.86) and ampl1q (HR, 1.67; 95% CI, 1.37 to 2.04) were significant adverse prognostic factors. The median duration of maintenance was 33 months (interquartile range 13-86 months). Response ≥ complete response (CR) after consolidation versus no consolidation before start of maintenance was 34% versus 18%, respectively (P < .001). Response ≥ CR on protocol including maintenance was 59% with consolidation and 46% without (P < .001). Minimal residual disease analysis by flow cytometry in a subgroup of 226 patients with CR or stringent complete response or very good partial response before start of maintenance demonstrated a 74% minimal residual disease-negativity rate in VRD-treated patients. Toxicity from VRD was acceptable and manageable. CONCLUSION: Consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and depth of response in newly diagnosed patients with multiple myeloma as compared to maintenance alone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sonneveld P, Dimopoulos MA, Beksac M, et al. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021. PMID: 34520219. doi:10.1200/JCO.21.01045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。